Name：Kang Kang

Position：Associate Professor

E-mail：[email protected]

Personal Statement:

Dr. Kang currently serves as an Associate Professor and Doctoral Supervisor at Shenzhen University, holding the distinction of Shenzhen High-Level Professional Talent. With a Ph.D. in Biochemistry and Molecular Biology from South China Agricultural University (2010) and postdoctoral training at Shenzhen University (2014), he leads research in the Department of Biochemistry and Molecular Biology under the School of Basic Medical Sciences. His academic responsibilities include designing curricula for graduate and undergraduate programs such as Biochemical Principles, Molecular Biology Laboratory, and Medical Molecular Biology.

Internationally recognized for pioneering the S-Poly(T) methodology—an ultrasensitive miRNA detection platform advancing early diagnosis of tumors and cardiovascular diseases—Dr. Kang has authored 40+ SCI-indexed papers in top journals (e.g., CMBL, CMLS, JASB, and JBC) and secured 20 patents (8 granted). As Principal Investigator for 2 NSFC General Programs and 3 Shenzhen Municipal Grants, his research focuses on non-coding RNA regulation in renal water-salt balance, vascular remodeling mechanisms, and liquid biopsy innovation. His contributions earned the 2021 Guangdong Science & Technology Award (Natural Science Second Prize) and were showcased at the Shenzhen High-Tech Fair, underscoring his translational impact on precision medicine.

Research Interests:

Non-coding RNAs/RNA methylation in vascular remodeling.

Physiological stress, non-coding RNAs, and cellular homeostasis.

cfRNA/cfDNA/direct PCR-based liquid biopsy for major diseases (cancer, cardiovascular diseases, infectious diseases).

Research Projects:

1. NSFC General Program (82270054): CARMN/miR-143/145 cluster m6A modification in pulmonary artery smooth muscle cell phenotype regulation. 01/01/2023 to 12/31/2026. ￥520,000

2. NSFC General Program (31571199): microRNAactivated NFAT5 pathway in renal medullary cell hyperosmotic stress.01/01/2016 to 12/31/2019. ￥720,000

3. Shenzhen Basic Research Project (JCYJ20240813142629039): Long non-coding RNA CARMN in pulmonary vascular remodeling. 01/01/2024 to 12/31/2027. ￥300,000

Selected Peer-reviewed Publications:

1. Kang K^#, Sun C, Li H, Liu X, Deng J, Chen S, Zeng L, Chen J, Liu X, Kuang J, Xiang J, Cheng J, Liao X, Lin M, Zhang X, Zhan C, Liu S, Wang J, Niu Y, Liu C, Liang C, Zhu J, Liang S, Tang H, Gou D*. N6-methyladenosine-driven miR-143/145-KLF4 circuit orchestrates the phenotypic switch of pulmonary artery smooth muscle cells. Cellular and Molecular Life Sciences 2024;81:256.

2. Kang K^#, Xiang JJ, Zhang XS, Xie YT, Zhou MT, Zeng L, Zhuang JH, Kuang JH, Lin YY, Hu BZ, Xiong QM, Yin Q, Su Q, Liao XY, Wang J, Niu YQ, Liu CL, Tian JL, Gou DM*. N6-methyladenosine modification of KLF2 may contribute to endothelial-to-mesenchymal transition in pulmonary hypertension. Cellular & Molecular Biology Letters 2024;29.

3. Kang K^#, Huang L, Li Q, Liao XY, Dang QJ, Yang Y, Luo J, Zeng Y, Li L, Gou DM*. An improved Tet-on system in microRNA overexpression and CRISPR/Cas9-mediated gene editing. Journal of Animal Science and Biotechnology 2019;10.

4. Kang K^#, Liao XY, Li Q, Chen JD, Niu YQ, Zeng Y, Xia SJ, Zeng L, Liu S, Gou DM*. A novel tonicity-responsive microRNA miR-23a-5p modulates renal cell survival under osmotic stress through targeting heat shock protein 70 HSPA1B. Am J Physiol-Cell Ph 2021;320:C225-C239.

5. Kang K^#, Peng X, Zhang X, Wang Y, Zhang L, Gao L, Weng T, Zhang H, Ramchandran R, Raj JU, Gou D*, Liu L*. MicroRNA-124 suppresses the transactivation of nuclear factor of activated T cells by targeting multiple genes and inhibits the proliferation of pulmonary artery smooth muscle cells. J Biol Chem 2013;288:25414-25427.